Novo Nordisk A/S (NYSE:NVO) Shares Sold by Montis Financial LLC

Montis Financial LLC lessened its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 26.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 10,218 shares of the company's stock after selling 3,741 shares during the quarter. Montis Financial LLC's holdings in Novo Nordisk A/S were worth $710,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in NVO. Bailard Inc. lifted its stake in shares of Novo Nordisk A/S by 49.3% in the first quarter. Bailard Inc. now owns 12,968 shares of the company's stock worth $900,000 after buying an additional 4,282 shares in the last quarter. Hudock Inc. increased its position in Novo Nordisk A/S by 45.6% during the first quarter. Hudock Inc. now owns 7,731 shares of the company's stock worth $537,000 after purchasing an additional 2,423 shares during the last quarter. Legacy Capital Wealth Partners LLC increased its position in Novo Nordisk A/S by 23.3% during the first quarter. Legacy Capital Wealth Partners LLC now owns 6,578 shares of the company's stock worth $457,000 after purchasing an additional 1,241 shares during the last quarter. Welch & Forbes LLC increased its position in Novo Nordisk A/S by 1.7% during the first quarter. Welch & Forbes LLC now owns 21,546 shares of the company's stock worth $1,496,000 after purchasing an additional 370 shares during the last quarter. Finally, Altman Advisors Inc. increased its position in Novo Nordisk A/S by 121.1% during the first quarter. Altman Advisors Inc. now owns 35,260 shares of the company's stock worth $2,343,000 after purchasing an additional 19,309 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

NVO has been the subject of several recent analyst reports. BMO Capital Markets restated a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Finally, Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Stock Down 1.5%

Shares of NVO stock traded down $0.97 during trading on Friday, reaching $64.32. The company's stock had a trading volume of 8,032,293 shares, compared to its average volume of 7,373,465. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $139.74. The company has a market capitalization of $287.19 billion, a price-to-earnings ratio of 19.03, a P/E/G ratio of 1.29 and a beta of 0.64. The stock's 50-day moving average price is $70.37 and its 200 day moving average price is $74.53.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The business had revenue of $11.87 billion during the quarter. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.